University of Edinburgh

Multiomic Study Points to New Colorectal Cancer Risk Contributors

Researchers tracked down more than 100 new risk variants with a combination of genomic, transcriptomic, and methylation analyses, highlighting new and known risk pathways.

Nuvectis Pharma Grows Precision Oncology Pipeline With University of Edinburgh's SRC/YES1 Inhibitor

The company will begin IND-enabling studies of NXP900 this year and develop it as a treatment for various solid tumors.

Scottish Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding

The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials.

University of Edinburgh

Multiomic Study Points to New Colorectal Cancer Risk Contributors

Nuvectis Pharma Grows Precision Oncology Pipeline With University of Edinburgh's SRC/YES1 Inhibitor

Scottish Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding

Biomarker Identification a Challenge and Opportunity in Cancer Drug Development, Survey Finds

Sanofi Inks €100M Radiopharmaceutical Deal With RadioMedix, Orano Med

Columbia University Leads Project Studying Impact of Genetics, Environment on Drug Responses

Meta-Analysis Questions FDA Warning on Secondary Cancer Risks With CAR T-Cell Therapies

Vir Biotechnology Completes Licensing Deal With Sanofi for Three T-Cell Engager Programs

BridgeBio Discontinues Development of Gene Therapy for Congenital Adrenal Hyperplasia